anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The aim of the following review is to shed light on the putative role of regulatory B cells (Bregs) in various human diseases and highlight their potential prognostic and therapeutic relevance in humans. Regulatory B cells are a heterogeneous group of B lymphocytes capable of suppressing inflammatory immune reactions. In this way, Bregs contribute to the maintenance of tolerance and immune homeostasis by limiting ongoing immune reactions temporally and spatially. Bregs play an important role in attenuating pathological inflammatory reactions that can be associated with transplant rejection, graft-versus-host disease, autoimmune diseases and allergies but also with infectious, neoplastic and metabolic diseases. Early studies of Bregs identified IL-10 as an important functional molecule, so the IL-10-secreting murine B10 cell is still considered a prototype Breg, and IL-10 has long been central to the search for human Breg equivalents. However, over the past two decades, other molecules that may contribute to the immunosuppressive function of Bregs have been discovered, some of which are only present in human Bregs. This expanded arsenal includes several anti-inflammatory cytokines, such as IL-35 and TGF-β, but also enzymes such as CD39/CD73, granzyme B and IDO as well as cell surface proteins including PD-L1, CD1d and CD25. In summary, the present review illustrates in a concise and comprehensive manner that although human Bregs share common functional immunosuppressive features leading to a prominent role in various human immunpathologies, they are composed of a pool of different B cell types with rather heterogeneous phenotypic and transcriptional properties.
PURPOSE: A composition containing Taxifolin 3-O-β-DGlucopyranoside for treating atopic dermatitis is provided to suppress COX-2(cyclooxygenase-2) and iNOS(inducible Nitric Oxide Synthase) and to reduce eosinophile and IL-4, 5, and 13 level. CONSTITUTION: A pharmaceutical composition for preventing or treating atopic dermatitis contains Taxifolin 3-O-β-DGlucopyranoside of chemical formula 1 and a pharmaceutically acceptable carrier. The Taxifolin 3-O-β-DGlucopyranoside is isolated from Rhododendron mucronulatum roots. The composition is used in the form of a powder, gel, ointment, cream, liquid, or aerosol. A cosmetic composition for relieving atopic dermatitis contains Taxifolin 3-O-β-DGlucopyranoside of chemical formula 1 and a cosmetically acceptable carrier. The composition is used in the form of a paste, gel, cream, gel, lotion, powder, soap, surfactant-containing cleansing oil, wax foundation, or spray.
Poverty has been identified as a powerful predictor of child maltreatment and child welfare involvement. Recent research shows that even modest economic and concrete supports are associated with reduced child maltreatment and involvement with child welfare. Toward that end, the New York State Office of Children and Family Services (OCFS), in partnership with the Office of Temporary Disability Assistance (OTDA) and the Center for Guaranteed Income Research (CGIR), University of Pennsylvania is conducting on randomized controlled trial of unconditional cash transfers among families with prior child welfare referrals in three New York counties in 2023.

The project will enroll approximately 150 households in Monroe, Onondaga, and Westchester counties to receive $500 per month, unconditionally, over a one-year period, totaling $6,000 per family. Another 300 will be assigned to the control group and will not receive the unconditional cash transfers but will be eligible to participate in research activities. Families will be eligible if they were served through differential response, called Family Assessment Response (FAR) in New York State. FAR is used for CPS reports that have been accepted by the New York State Central Register for Child Abuse and Maltreatment (SCR) where there is no safety concern that rises to the level of immediate or impending danger for the child and/or family. Often, families served in the FAR track have been referred for poverty-related social needs.

Randomized Controlled Trial Design: Households referred and determined eligible for Family Assessment Response (FAR) will be invited to participate in a randomized controlled trial of unconditional cash transfers. Approximately 150 individuals will be randomly assigned to the treatment group and will receive the $500 unconditional cash transfers for one year. Another 300 will be assigned to the control group and will not receive the unconditional cash transfers but will be eligible to participate in research activities. Youth Research Inc. (YRI), an agency contracted by the New York Office of Child and Family Services (OCFS), will disburse funds on a debit card. me but will be invited to participate in compensated research activities. Longitudinal repeated measures will be utilized through surveys conducted at baseline, 6 months, 12 months, and 18 months. Future involvement with child welfare will be measured using linked administrative data from OCFS.
M2VA case managers at sites randomized to IF+TAU will receive the M2VAPCP training workshop described above and IF delivered virtually for 21 months after receiving the M2VAPCP training workshop. IF for this trial will be organized around three major components: 1) an external facilitation team consisting of clinical and implementation experts who will work with internal facilitators at each site; 2) multifaceted activities to support the use of M2VAPCP; and 3) ongoing formative evaluation.
A century ago, Sampson identified three uterine anatomical structures that may determine the amount of retrograde menstruation and the likelihood of the development of endometriosis: the cervix, the intramural portion of the fallopian tubes, and the myometrium. Critical appraisal was undertaken of data published over the last 40 years on the potential effect of the characteristics of these three anatomical variables on the risk of endometriosis. There is some evidence to support the pathogenic role of the diameter of the cervical canal, stenosis of internal or external orifices, and stiffness of cervical tissue. One study showed a significant association between the morphology of the intramural tubal tract and the frequency of endometriosis. A large body of evidence points to abnormalities of the myometrial structure as the anatomical aberration most consistently associated with endometriosis. These abnormalities have largely been interpreted as signs of early-onset adenomyosis, which may precede endometriosis and even lead to its development by increasing the amount of retrograde menstruation. Future research should aim to verify whether a positive relationship exists between the substantially increased number of ovulatory menses occurring in the decade following menarche, the development of anatomical myometrial abnormalities, changes in the amount of retrograde menstruation over time, and the risk of endometriosis.
The study will recruit 210 schizophrenia patients who meet the criteria of DSM-4, and then randomized to 3 groups: control group, probiotics group and prebiotics group for a 14-weeks clinical trail and 12-weeks follow-up period. In addition to probiotics, prebiotic or maltodextrin interventions, in the meantime, all participants will also use one of the prescribed antipsychotics medications. Clinical efficacy and safety assessment will be done at baseline, clinical trail and follow-up period. The specific aims are to evaluate these tips: 1) psychotic syndrome; 2) cognition; 3) Gastrointestinal function; 4) inflammatory and metabolic related markers. Psychotic syndrome will be measured by the Positive and Negative Syndrome Scale. Cognitive function will be assessed by the MATRICS Consensus Cognitive Battery. Gastrointestinal function will be assessed by gastrointestinal symptom assessment scale (GSRS). Biological samples also will be collected, and stored to research Intestinal inflammation, intestinal permeability, intestinal flora and other indicators.
Tourette syndrome (TS) is characterized by multiple motor and phonic tics. Current understanding of tic generation is thought involve the cortico-basal-thalamic-cortical circuit. At this time, only two medications are FDA-approved for tic treatment, while many more are used in an off-label fashion with only partial success. Despite multiple approaches for tic suppression, patients with severe tics are often left with inadequate relief. Repetitive Transcranial Magnetic Stimulation (RTMS) is a new technology which allows for noninvasive stimulation of the brain. In few pilot studies, RTMS reduced tic severity when targeting the Supplementary Motor Area (SMA). In this study, we propose to use a specific paradigm of RTMS called Continuous Theta Burst Stimulation (cTBS) over SMA to treat pediatric and adult patients with tics. We will utilize functional MRI (fMRI) to identify each subject's SMA for individualized stimulation. We hypothesize that this stimulation technique can reduce tic severity when compared to sham stimulation. This proposal is novel because 1) cTBS is offered as a new RTMS paradigm to reduce tics and 2) combination of RTMS and fMRI allows us to investigate the effects of cortical stimulation on the neural correlates of tic generation.
Rhabdomyolysis (RM) leads to dysfunction in the core organs of kidney, lung and heart, which is an important reason for the high mortality and disability rate of this disease. However, there is a lack of systematic research on the characteristics of rhabdomyolysis-induced injury in various organs and the underlying pathogenetic mechanisms, and especially the interaction between organs. We established a rhabdomyolysis model, observed the structural and functional changes in kidney, heart, and lung. It is observed that rhabdomyolysis results in significant damage in kidney, lung and heart of rats, among which the pathological damage of kidney and lung was significant, and of heart was relatively light. Meanwhile, we analyzed the differentially expressed proteins (DEPs) in the kidney, heart and lung between the RM group and the sham group based on liquid chromatography-tandem mass spectrometry (LC-MS/MS). In our study, Serpina3n was significantly up-regulated in the kidney, heart and lung. Serpina3n is a secreted protein and specifically inhibits a variety of proteases and participates in multiple physiological processes such as complement activation, inflammatory responses, apoptosis pathways, and extracellular matrix metabolism. It is inferred that Serpina3n may play an important role in multiple organ damage caused by rhabdomyolysis and could be used as a potential biomarker. This study comprehensively describes the functional and structural changes of kidney, heart and lung in rats after rhabdomyolysis, analyzes the DEPs of kidney, heart and lung, and determines the key role of Serpina3n in multiple organ injury caused by rhabdomyolysis. SIGNIFICANCE: This study comprehensively describes the functional and structural changes of kidney, heart and lung in rats after rhabdomyolysis, analyzes the DEPs of kidney, heart and lung, and determines the key role of Serpina3n in multiple organ injury caused by rhabdomyolysis.
Volunteers will return to the clinic after Baseline for 10 additional, consecutive days for study staff to apply approximately 2 mg/cm2 or 50 µL of test product to the appropriate 5x5cm2 test location on the lower back. Volunteers will have digital images of the three (3) areas on the lower back that comprise the entire test region taken at Baseline, and 24hrs post 90J/cm2 HEV light exposure.
PURPOSE:To obtain the titled agent by neutralizing an acidic aqueous solution of a phytic acid salt in the presence of a component selected from amino acids, peptides and water-soluble proteins, and using the resultant precipitate as an active component. CONSTITUTION:An acidic aqueous solution of a phytic acid salt (e.g. a double salt of phytic acid and a cation composed mainly of magnesium and potassium) is neutralized in the presence of one or more components selected from amino acids (e.g. glycine, alanine, valine, methonine, serine, asparagin, etc.), peptides (e.g. glycylglycine, glycylglycylglycine, etc.) and water-soluble proteins (e.g. albumin, casein, etc.), and the precipitate is used as an active component of the objective remedy and preventive for hypercalciuria. It is administered in the form of powder, tablet, etc., at a dose of 600-800mg in terms of the phytic acid salt orally after meal.
China is home to the 18% of the world's blind people, an estimated 6.6 million. In China, cataract is the leading cause of blindness. In Guangdong, current counseling measures for patients diagnosed with cataract are minimal and often lack adequate descriptions of what cataract is, what causes cataract, and benefits/risks of surgery. A counseling session for cataract patients and family members, conducted by a trained nurse during outreach screening, may increase subsequent attendance at pre-operative examination, acceptance of cataract surgery, and attendance at follow-up examinations. An integral part of this counseling is a short movie consisting of testimony from a former cataract patient who underwent surgery ("pseudophakic motivator"). The use of pseudophakic motivators have been shown to be effective in increasing surgical uptake. In addition, a previously validated "Barriers Questionnaire" will be used to assess predictors of of hospital attendance, surgery acceptance, and follow-up attendance in the categories of cost, transportation, knowledge, and concerns about quality.
An application file defines a first data object that identifies a fast healthcare interoperability resources (FHIR) server and a second data object that identifies a data type associated with the FHIR server. Based on the first data object and the second data object, a FHIR model requests data of the data type from the FHIR server. The FHIR server provides the requested data, which is received by the FHIR model. Based on the received data, the FHIR model generates data in a user interface (UI) control format and provides the generated data to a UI module that causes a UI to be presented. The FHIR model supports binding of complete entities such as patients or organizations to a UI. This binding enables the requesting of whole entities from a FHIR endpoint, provision of the entity data to the UI, and updating the FHIR data.
Steroid eye drops: 1 drop each eye, 3 times/day, starting 2 days prior to depatuxizumab mafodotin infusion and continuing until 4 days after infusion, for a total of 7 days; Vasoconstrictor Eye Drops: 1 drop each eye 4 - 6 times on day of infusion in total (5 - 10 minutes before infusion; at end of infusion; and 2 - 4 times during the remainder of the infusion day). Continuing 4 - 6 times/day on Day 1 and Day 2 after each depatuxizumab mafodotin infusion; Cold Compress: Starting 5 minutes prior to start of infusion and continuing for 30 minutes past end of infusion, and then use at least 2 hours total/day on Days 1 - 3 with each depatuxizumab mafodotin infusion. The cold compress was to be applied in increments no longer than 30 min (could be shorter if the participant was uncomfortable).
BACKGROUND: The purpose of this study was to investigate the protective effect of dexmedetomidine (DEX) on sep¬sis-induced acute kidney injury (AKI) and its possible mechanisms.
METHODS: A total of 40 mice were randomly divided into the control group (C group), lipopolysaccharide treatment group (LPS group), LPS+DEX group, and ferrostatin-1 group (LPS+Fer-1 group). Mice in the LPS group were intraperitoneally injected with LPS (10 mg/kg), while mice in the LPS+DEX and LPS+Fer-1 groups were intraperitoneally injected with Dex (30 μg/kg) and Fer-1 (10 mg/kg), 1 hour before LPS injection, respectively. Mice in the control group were infused with the same volume of saline. Serum creatinine (SCr), blood urea nitrogen (BUN) and the levels of superoxide dismutase (SOD), malondialdehyde (MDA), and total antioxidant capacity (T-AOC) in renal tissue were measured. HE staining was used to evaluate the degree of kidney tissue injury. Immunohistochemistry and western blot were used to detect the protein expressions of FTH, TFR, Keap1, and Nrf2 in kidney tissue.
RESULTS: Compared with the control group, the serum levels of SCr and BUN were significantly increased, the levels of SOD and T-AOC in the kidney were decreased, the MDA level and renal injury score were increased, the expression of FTH and Nrf2 protein was reduced, and the expression of TFR and Keap1 protein was increased in the LPS group (p < 0.05). Compared with the LPS group, the serum levels of SCr and BUN were significantly de-creased, the levels of SOD and T-AOC in the kidney were increased, the MDA level and renal injury score were decreased, the expression of FTH and Nrf2 protein was increased, and the expression of TFR and Keap1 protein was decreased in the LPS+DEX group (p < 0.05).
CONCLUSIONS: Dex can alleviate sepsis-associated acute kidney injury by activating the Keap1/Nrf2 pathway.
PURPOSE:To obtain the titled antibody from a cultured product obtained by preparing a mouse-human hybridoma from a human simple herpes virus antibody-producing cell and a mouse myeloma cell, and culturing said hybridoma and/or a cell strain derived therefrom. CONSTITUTION:A mouse-human hybridoma is prepared from a human simple herpes virus antibody-producing cell and a mouse myeloma cell (e.g. P3X63Ag8 strain of BALB/C mouse), and the hybridoma and/or a cell strain derived therefrom is cultured. The objective human monoclonal antibody to simple herpes virus can be separated from the cultured product. The monoclonal antibody is reactive with the cell membrane and cytoplasm of cell infected with simple herpes virus type-1 or type-2, and almost nonreactive with noninfected cell. It is an IgG-type antibody having a molecular weight of about 160,000. The human antibody-producing cell (lymphocyte) is sensitized in the presence of mitogen in vitro prior to the cell fusion.
Recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is a challenging disease, requiring personalized management by a multidisciplinary team. The aim of this retrospective multicentric study was to characterize real-world healthcare resource use and patient care for R/M HNSCC in Portugal during the first year after diagnosis. A total of 377 patients ineligible for curative treatment were included, mostly male (92.8%), aged 50-69 years (74.5%), with heavy alcohol (72.7%) or smoking habits (89.3%). Oropharynx (33.2%) and oral cavity (28.7%) were primary tumor locations, with lung metastases being the most common (61.4%). Eligible patients for systemic treatment with palliative intent (80.6%) received up to four treatment lines, with varied regimens. Platinum-based combination chemotherapy dominated first-line treatment (>70%), while single-agent chemotherapy and anti-PD1 immunotherapy were prevalent in later lines. Treatment approaches were uniform across disease stages and primary tumor locations but varied geographically. Treated patients received more multidisciplinary support than those who were ineligible. This study provides the first Portuguese real-world description of R/M HNSCC patient characteristics, treatment patterns, and supportive care during the year after diagnosis, highlighting population heterogeneity and aiming to improve patient management.
Patients will be given a VAS scale to record their highest level of pain 6 hrs prior to treatment. The standard endodontic protocol will be followed. The same VAS scale from pretreatment will be used to record pain level at 6, 24, 72, and 168 hours post-treatment.
I.v. iron administration in the form of FCM will be carried out according to SmPC. I.v. iron bolus administration (1000 mg) will be followed by an optional administration of 500-1000 mg within the first 4 weeks, (up to a total of 2000 mg which is in-label), according to the approved dosing rules, followed by administration of 500 mg FCM at every 4 months, except when haemoglobin is \> 16.0 g/dL or ferritin is \> 800 µg/L .In the verum group, all patients will receive a saline administration, when no iron is indicated at the time of the visit and according to the values listed above.
PURPOSE: Precise identification of lymph node metastases is vital for the management of cervical cancer. However, the existing diagnostic methods for lymph node metastases have certain drawbacks. In this study, we aim to explore the expression of cancer-associated fibroblasts (CAFs) and tumor-to-stroma CD8+ T cells ratio (CD8+ T cells T:S ratio) and its association with lymph node metastases of cervical cancer.
METHODS: Hundred and ten cervical cancer tissues and 39 biopsy tissues from patients were investigated immunocytochemically for the expression of CAFs and CD8+ T cells. The statistical correlation analysis was carried out using the SPSS system.
RESULTS: A strong and statistically significant negative correlation (r= - 0.690; P < 0.001) was observed between CAF density and CD8+ T cells T:S ratio. Not only were CAFs density and CD8+ T cells T:S ratio correlated with lymph node metastases respectively (P < 0.001), but the combination of them also significantly correlated with lymph node metastases (P < 0.001). Then, we constructed the combined diagnosis model (Logit (P) = - 4.446 + 0.300 × CAFs + 0.752 × CD8+ T cells T:S Ratio) of cervical cancer lymph node metastases. ROC curves analysis showed that the ROC curves areas for CAFs, CD8+ T cells T:S ratio, and a combination of both are 0.879, 0.747, and 0.951. Then, the prediction model was verified by biopsy specimens and consistent results were obtained.
CONCLUSIONS: The combination of CAF density and CD8+ T cells T:S ratio has a significant predictive value for lymph node metastases in patients with cervical cancer.
In addition to the spinal anesthesia and femoral block, the anesthesia of the sciatic nerve at the top of the popliteal fossae was realized, also guided by ultrasonography (Nemio 17 - Toshiba Systems Co. - Japan) and neurosimulation (Stimuplex HNS 12 - Braun - Germany) with 1 Hz stimulus frequency, 1.2 to 0.5 mA energy. 0.5% ropivacaine was injected associated to 75mcg clonidine.
Congenital heart defects (CHDs) are one of the most common congenital malformations and often require heart surgery with cardiopulmonary bypass (CPB). Children undergoing cardiac surgery with CPB are especially at greater risk of post-operative complications due to a systemic inflammatory response caused by innate inflammatory mediators. However, the pathophysiological response is not fully understood and warrants further investigation. Therefore, we investigated the inflammatory response in macrophages initiated by peri-operative serum samples obtained from patients with CHD undergoing CPB cardiac surgery. Human differentiated THP-1 macrophages were pretreated with Stattic, a STAT3 (Tyr705) inhibitor, before stimulation with serum samples. STAT3 and NF-κB activation were investigated via a Western blot, IL-1β, TNFα, IL-10, mediators for vascular permeability (VEGF-A, ICAM), and SOCS3 gene expressions via RT-qPCR. CPB induced an inflammatory response in macrophages via the activation of the STAT3 but not NF-κB signaling pathway. Longer duration on the CPB correlated with increased cytokine, VEGF, and ICAM expressions, relative to individual pre-operation levels. Patients that did not require CPB showed no significant immune response. Pretreatment with Stattic significantly attenuated all inflammatory mediators investigated except for TNFα in the macrophages. CPB induces an increased expression of cytokines and mediators of vascular permeability via the activation of STAT3 by IL-6 and IL-8 in the serum samples. Stattic attenuates all mediators investigated but promotes TNFα expression.
Muscle therapy for the lumbar spine at the StimaWell 120MTRS system's phasic setting. Treatment at 3 kHz, modulation 50 Hz. Supervised 10 week intervention, 2 times a week. Treatment time of 20 minutes for the first 3 weeks, 25 minutes for the second 3 weeks, and 30 minutes for the final 4 weeks. 120MTRS system recalibration every fifth treatment.